3SBio: Balancing Growth Prospects With Financial Challenges – A Hold Rating by Sean Wu, CFA
Bank of China International Downgrades CSPC Pharmaceutical to Hold From Buy; Price Target Is HK$6.50
Nomura Adjusts Sino Biopharmaceutical's Price Target to HK$6.42 From HK$6.16, Keeps at Buy
HUTCHMED (China) Analyst Ratings
Hold Rating on HUTCHMED Amid Promising U.S. Launch and Pending EU Reimbursement Clarity
Nomura Adjusts Hansoh Pharmaceutical's Price Target to HK$17.23 From HK$15.03, Keeps at Neutral
Nomura Adjusts CSPC Pharmaceutical's Price Target to HK$9.83 From HK$10.07, Keeps at Buy
Nomura Adjusts Innovent Biologics' Price Target to HK$55.87 From HK$55.31, Keeps at Buy
Nomura Adjusts Asymchem Laboratories (Tianjin)'s Price Target to 107.91 Yuan From 118.48 Yuan, Keeps at Buy
Nomura Adjusts Asymchem Laboratories (Tianjin)'s Price Target to HK$76.45 From HK$83.94, Keeps at Buy
Goldman Sachs Keeps Their Hold Rating on HUTCHMED (HCM)
Nomura Adjusts CSPC Pharmaceutical's Price Target to HK$10.07 From HK$9.41, Keeps at Buy
Analysts' Opinions Are Mixed on These Healthcare Stocks: HUTCHMED (HCM) and PAVmed (PAVM)
Nomura Adjusts Asymchem Laboratories' Price Target to 118.48 Yuan From 127.21 Yuan Keeps at Buy
Analysts Offer Insights on Healthcare Companies: 3SBio (OtherTRSBF), UnitedHealth (UNH) and Caribou Biosciences (CRBU)
Nomura Adjusts Sino Biopharmaceutical's Price Target to HK$6.16 From HK$6.63, Keeps at Buy
Nomura Adjusts CSPC Pharmaceutical Group's Price Target to HK$9.41 From HK$8.98, Keeps at Buy
Nomura Adjusts Asymchem Laboratories Tianjin's Price Target to HK$90.12 From HK$134.59, Keeps at Buy
HUTCHMED Hold Rating: Cautious Optimism Amidst Stable Outlook and International Growth Potential
Nomura Adjusts Innovent Biologics' Price Target to HK$55.31 From HK$54.51, Keeps at Buy